Načítá se...
Venetoclax-based Therapies for Acute Myeloid Leukemia
The prognosis of adult acute myeloid leukemia (AML) remains poor, with the long-term survival rate less than 50%. However, the current paradigms of treatment are changing through a better understanding of the disease genetics and pathophysiology. Since 2017, eight new drugs have been approved by the...
Uloženo v:
| Vydáno v: | Best Pract Res Clin Haematol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6581210/ https://ncbi.nlm.nih.gov/pubmed/31203996 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.beha.2019.05.008 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|